In patent fight versus Pfizer generic, Astellas gets good news and bad
In patent fight versus Pfizer generic, Astellas gets good news and ba
Lipocine seeks partner for midphase NASH asset in pivot to oral CNS drugs
Lipocine seeks partner for midphase NASH asset in pivot to oral CNS d
Seeking sibling for Vyvgart, argenx files for FDA approval of subcutaneous efgartigimod
Seeking sibling for Vyvgart, argenx files for FDA approval of subcuta
Satsuma peels off fresh strip of long-term migraine study data ahead of planned FDA filing
Satsuma peels off fresh strip of long-term migraine study data ahead
Daiichi Sankyo bags an industry first with Japanese nod for blood cancer drug Ezharmia
Daiichi Sankyo bags an industry first with Japanese nod for blood can
In patent fight versus Pfizer generic, Astellas gets good news and bad
In patent fight versus Pfizer generic, Astellas gets good news and ba
Lipocine seeks partner for midphase NASH asset in pivot to oral CNS drugs
Lipocine seeks partner for midphase NASH asset in pivot to oral CNS d
Seeking sibling for Vyvgart, argenx files for FDA approval of subcutaneous efgartigimod
Seeking sibling for Vyvgart, argenx files for FDA approval of subcuta
Satsuma peels off fresh strip of long-term migraine study data ahead of planned FDA filing
Satsuma peels off fresh strip of long-term migraine study data ahead
Daiichi Sankyo bags an industry first with Japanese nod for blood cancer drug Ezharmia
Daiichi Sankyo bags an industry first with Japanese nod for blood can
© 1994 - 2022 B.M. Pharmaceuticals